Our clinical programs are leading the field
Explore the scientific evidence supporting GRAIL’s multi-cancer early detection approach, including peer-reviewed publications and presentations at leading medical congresses. Together, these data highlight test performance, clinical utility, and progress toward transforming cancer screening.
Foundational data
Case-control study
Annals of Oncology
Read Full Article
Prospective screening study
Nature Medicine
Read Full Article
Randomized control study
Nature Medicine
Read Full Article
Prospective real-world study
Nature Communications
Read Full Article
Featured evidence
European Society for Medical Oncology (ESMO) 2025
Safety and Performance of a Multi-Cancer Early Detection (MCED) Test in an Intended Use Population: Initial Results from the Registrational PATHFINDER 2 Study
See Presentation
JCO Precision Oncology
Prognostic Significance of Blood-Based Multicancer Detection in Circulating Tumor DNA: Five-Year Outcomes of Analysis
Read Full Article
Cancer Prevention Research
Molecular Cancer Signal Localization in MCED Testing Minimizes Radiation and Imaging Burden Compared with Whole-body Imaging Approaches
Read Full Article
American Association of Cancer Research (AACR) 2026
Association Between Emergency Department (ED) Involvement in Cancer Diagnosis and Survival Across Cancer Types in the Medicare Population
See Presentation
Manuscripts
Real-world data and clinical experience from over 100,000 multi-cancer early detection tests
View ManuscriptThe impact of cancer expectations on psychological responses following a cancer signal detected result in asymptomatic multi-cancer detection (MCED) testing
View ManuscriptImpact of Population Cancer Risk on the Cost-effectiveness of Multi-cancer Early Detection Testing in the US
View ManuscriptDurvalumab after radiotherapy in patients with unresectable stage III non-small-cell lung cancer ineligible for chemotherapy: the DUART phase II nonrandomized controlled study
View Manuscript